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Abstract
Background: Serum procalcitonin and high-sensitivity C-reactive protein (hs-CRP) elevations have been associated
with pneumonia in adults. Our aim was to establish their diagnostic usefulness in a cohort of hospitalized multimorbid
patients ≥65 years old admitted to hospital with acute respiratory symptoms.
Methods: With a retrospective cohort study design, all multimorbid patients ≥65 years-old with acute respiratory
symptoms admitted to an internal medicine hospital ward in Italy from January to August 2013 were evaluated.
Pneumonia diagnosis, comorbidities expressed through Cumulative Illness Rating Scale (CIRS), setting of living,
length of stay, serum hs-CRP and procalcitonin at admission were collected for each patient. Data were analyzed
with Mann-Whitney’s U test and multivariate Cox logistic regression analysis. A Receiver Operating Characteristic
(ROC) curve was used to verify each biomarker’s association with pneumonia diagnosis.
Results: Four hundred fifty five patients (227 M) were included in the study, of whom 239 with pneumonia (138 M,
mean age 80 ± 13) and 216 without pneumonia (89 M, mean age 80 ± 14). After adjustment for age and sex, median
levels of hs-CRP were significantly higher in patients with pneumonia (116 mg/L, IQR 46.5–179.0, vs 22.5 mg/dl, IQR
6.9–84.4, p < 0.0001), while procalcitonin median levels were not (0.22 ng/ml IQR 0.12–0.87, vs 0.15 ng/ml, IQR
0.10–0.35, p = 0.08). The ROC analysis showed that, unlike procalcitonin, hs-CRP values were predictive of pneumonia
(AUC 0.76, 95 % CI 0.72–0.79, p < 0.0001, cut-off value 61 mg/L), even after adjustment for possible confounders including
nursing home residence and dementia. Serum hs-CRP levels >61 mg/L were independently associated with a 3.59-fold
increased risk of pneumonia (OR 3.59, 95 % CI 2.35–5.48, p < 0.0001).
Conclusion: In elderly multimorbid patients who require hospital admission for respiratory symptoms, serum hs-CRP
testing seems to be more useful than procalcitonin for guiding the diagnostic process when clinical suspicion of
pneumonia is present. Procalcitonin testing might hence be not recommended in this setting.
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Background
Community-acquired pneumonia (CAP) and healthcare-
related pneumonia (HCAP) are highly prevalent in the
multimorbid elderly population, accounting also for a high
number of hospital admissions. In subjects aged ≥65 years,
CAP incidence of 14 per 1000 person-years has been
reported [1]. About 30 % of patients hospitalized
with pneumonia in industrialized countries live in
nursing homes, and thus these cases may be classi-
fied as HCAPs [2].
The diagnosis of pneumonia in elderly patients, what-
ever the healthcare setting of provenience, is often chal-
lenging. Signs and symptoms, including dyspnea, may be
vague or non-diagnostic, chest X-ray (CXR) findings may
be inconclusive and comorbidities may act as confounders
[3]. Therefore, the use of biomarkers of inflammation or
infection, such as procalcitonin and C-reactive protein
(CRP), has been proposed as a guide in the diagnostic
process [4].
The role of these two biomarkers in acute-care settings
has been extensively studied in recent years. The useful-
ness of procalcitonin in patients with unclear respiratory
symptoms has been particularly emphasized [5–7]. This
biomarker has been demonstrated as useful for differen-
tiating pneumonia from other acute clinical conditions
[8–11] and for establishing the prognosis [12–16]. How-
ever, some studies carried out in different settings, such
as acute-care wards [17], intensive care units (ICUs) [18]
and primary care [19, 20], questioned these assumptions.
CRP is a well-established biomarker in many clinical set-
tings, but has been traditionally considered not enough
specific to be a useful guide in the diagnostic process of
pneumonia. In fact, virtually all infective, autoimmune,
ischemic and neoplastic diseases can contribute to in-
crease serum CRP values. Nevertheless, some studies have
confirmed that it may have a good performance in defining
pneumonia diagnosis and severity [21, 22].
Very few studies assessing the role of CRP and procal-
citonin in the diagnostic algorithms of pneumonia have
been focused on multimorbid elderly patients, with con-
troversial results [7, 17]. These patients, although repre-
senting the large majority of cases of pneumonia admitted
to acute-care hospital wards, are often excluded from
clinical studies due to the possible presence of multiple
confounders. However, this is the setting where efficient
biomarkers are mostly needed, considering also the
possible pitfalls of traditional diagnostic examinations,
such as CXR.
Therefore, the aim of the present retrospective obser-
vational study is to evaluate the role of procalcitonin
and high-sensitivity C-reactive protein (hs-CRP) in es-
tablishing the diagnosis of pneumonia in a cohort of
multimorbid patients over 65 years old admitted with re-
spiratory symptoms to an acute-care hospital ward.
Methods
Patients and methods
A retrospective evaluation on clinical records of all pa-
tients admitted from January 1st to August 31st 2013 to
the Internal Medicine and Critical Subacute Care Unit
of Parma University Hospital, Italy, was performed. This
unit mainly admits elderly frail multimorbid patients
from Emergency Department. To exclude possible cases
of hospital-acquired pneumonia (HAP), only patients
with no hospital admission in the previous 30 days were
included in the study. Additional inclusion criteria were
age ≥65 years old, presence of respiratory symptoms
(dyspnea, cough, sputum, hemoptysis, pleuritic pain) as
main reason of admission, absence of a well-defined ter-
minal condition with a survival prognosis <30 days and
presence of at least one of feature of frailty (grip strength
lower than 18 kg, reduced gait speed, forced bed rest, lack
of autonomy in activities of daily living, >5 % weight loss
in the previous 6 months) or a Rockwood Clinical Frailty
Scale score ≥5 [23, 24].
Data collection
For each eligible patient, age, sex, setting of living (com-
munity vs nursing home), length of stay in our unit,
pneumonia status, main diagnosis, chronic comorbidities,
CXR/chest Computed Tomography (CT) results and serum
levels of procalcitonin and hs-CRP at admission were col-
lected. The diagnosis of pneumonia was set through a posi-
tive chest imaging technique, usually CXR, performed in
every patient admitted to our unit with respiratory symp-
toms, while chest CT scan was performed in case of incon-
clusive CXR findings. Multimorbidity was measured with
the number of diagnoses and with Cumulative Illness
Rating Scale (CIRS) Comorbidity Score [25]. This index
is validated in scientific literature [26] and based on the
assignment of a score (from 0 to 4), equivalent to dis-
ease severity, to each of 14 items that represent possible
organs of systems that can be affected by a chronic
disease. CIRS Comorbidity Score is defined as the sum
of all scores assigned to 14 items.
hs-CRP was measured with a reference immunone-
phelometric assay on BN system (Siemens Healthcare,
Tarrytown, New York). The diagnostic cut-off of hs-
CRP was set by manufacturer at 5 mg/L, with a total
imprecision lower than 5 %. Procalcitonin was measured
with a validated immunoassay (B.R.A.H.M.S. Kryptor sys-
tem, BRAHMS, Hennigsdorf, Germany). The functional
sensitivity of this method is 0.04 ng/mL and the total im-
precision is comprised between 0.7 and 8.3 %.
According to the aims of the study, patients with
respiratory symptoms and a final diagnosis of pneumo-
nia and those with respiratory symptoms without pneu-
monia were analyzed separately. Serum levels of hs-CRP
and procalcitonin were routinely measured within 12 h
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from admission to Internal Medicine and Critical Sub-
acute Care Unit during the period of the study. Patients
with missing data or blood tests performed after 12 h from
admission were excluded from the final analysis.
Statistical analysis and data management
Data were analyzed using SPSS v.22.0 software (IBM,
Armonk, New York, USA) and SAS v.8.2 (SAS Institute
Inc., Cary, North Carolina, USA). When data distribu-
tion deviated significantly from normality, continuous
data were reported as median values and interquartile
range (IQR). Subjects with and without pneumonia were
compared using Mann–Whitney U test for continuous
variables and chi-square (χ2) test for categorical vari-
ables, adjusted for age and sex. Receiver Operating
Characteristic (ROC) curves were used to evaluate the
sensitivity and specificity of procalcitonin and hs-CRP
vs pneumonia diagnosis. Cut-off values were reported
with the area under the curve (AUC) being given with
its 95 % confidence interval (CI). The cut-off value was
calculated with the Youden index. Univariate and multi-
variate analysis with Cox regression models were then ap-
plied to identify parameters associated with pneumonia
diagnosis. Confounders were selected among those pa-
rameters that were significantly different between subjects
with and without pneumonia at univariate analysis.
Additional subgroup analyses were also performed ac-
cording to CAP/HCAP categorization and to positivity
or negativity of CXR, in order to verify the diagnostic ac-
curacy of procalcitonin and hs-CRP in these situations.
All p-values were two-tailed and were considered sig-
nificant for p < 0.05.
Ethics, consent and permissions
The study protocol was approved by local ethics commit-
tee (Comitato Etico per Parma), ID n. 39655. All phases of
the study were carried out in conformity with the princi-
ples expressed in the Declaration of Helsinki. Written in-
formed consent was obtained according to Italian law.
Results
The overall number of admissions performed from the
Emergency Department in Internal Medicine and Critical
Subacute Care Unit from January to August 2013 was
1567. On overall, 1115 patients were excluded for not
satisfying inclusion criteria. Namely, 744 patients were ex-
cluded since respiratory symptoms were not the main
cause of admission, 174 for age (i.e., being ≤65 years old),
101 for hospitalization in the 30-day period before admis-
sion and 93 for other reasons (terminality, lack of “frailty”
criteria, good performance status, missing data about hs-
CRP and procalcitonin, blood tests performed after 12 h
from admission). Thus, the final study population in-
cluded 455 patients (227 M, 228 F).
The number of patients discharged with a main diag-
nosis of pneumonia (P+ group) was 239 (138 M, 101 F,
mean age 80 ± 13 years). The other 216 patients (89 M,
127 F, mean age 80 ± 14) had not pneumonia despite ad-
mission for respiratory symptoms (P- group). The main
characteristics of these two groups and an age- and sex-
adjusted comparison are reported in Table 1.
Serum hs-CRP values at admission were significantly
higher in P+ than in P- group (median 116.0, IQR 46.5–
179.0, vs 22.5, IQR 6.9–84.4, mg/L, age- and sex-adjusted
p < 0.001) (Fig. 1), while procalcitonin values were not






p value, age and sex-adjusted
Age, mean ± standard deviation (years) 80 ± 14 82 ± 10 0.22
Men, number (%) 138 (58) 89 (41) 0.006
CIRS Comorbidity Score, median [IQR] 14 [10–17] 14 [10–18] 0.51
Number of comorbidities, mean ± standard deviation 3.9 ± 1.5 4.0 ± 1.3 0.75
Nursing home residents, number (%) 46 (19) 24 (11) 0.004
Ward length of stay, mean ± standard deviation (days) 4.9 ± 3.1 3.8 ± 2.1 <0.001
Inhospital death, number (%) 19 (8) 16 (7) 0.96
hs-CRP, median [IQR] (mg/L, normal range 0–5) 116.0 [46.5–179.0] 22.5 [6.9–84.4] <0.001
Procalcitonin, median [IQR] (ng/ml, normal range 0–0.50) 0.22 [0.12–0.87] 0.15 [0.10–0.35] 0.08
Dementia, number (%) 100 (42) 54 (25) <0.001
Stroke, number (%) 57 (24) 39 (18) 0.11
Cancer, number (%) 53 (22) 41 (19) 0.56
Liver disease, number (%) 31 (13) 21 (10) 0.53
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(median 0.22, IQR 0.12–0.87, vs 0.15, IQR 0.10–0.35,
ng/ml, age- and sex-adjusted p = 0.08) (Fig. 2).
The ROC analysis showed that hs-CRP values were
significantly associated with pneumonia (AUC 0.76,
95 % CI 0.72–0.79, age- and sex-adjusted p < 0.0001,
Fig. 3). Inclusion of other covariates that were signifi-
cantly different between P+ and P- groups (nursing
home residency and dementia) in the ROC model did
not change this result (AUC 0.78, 95 % CI 0.73–0.81,
fully-adjusted p < 0.0001). The cut-off value, with the
best sensitivity and specificity compromise, was set at
61 mg/L. On the other side, ROC analysis for procalci-
tonin confirmed that this biomarker is not significantly
associated with pneumonia in the studied population (AUC
0.54, 95 % CI 0.47–0.62, age- and sex-adjusted p = 0.20).
Univariate (model 1) and multivariate (model 2) Cox
regression models were then built to test the association
of hs-CRP values, dichotomized according to the ROC
method, with pneumonia diagnosis. These models are
shown in Table 2. Notably, after adjustment for multiple
potential confounders that were significantly different at
univariate analysis shown in Table 1, including age, sex,
dementia and provenience from nursing home, a serum
hs-CRP value >61 mg/L at admission was associated
with a 3.59-fold higher risk of pneumonia (OR 3.59,
95 % CI 2.35–5.48, fully-adjusted p < 0.0001).
Among patients with pneumonia, 46 were admitted
from a nursing home and therefore had HCAP (21 M,
25 F, mean age 82 ± 14 years), while 193 had been living
in the community and were classified as CAPs (117 M,
Fig. 1 Serum high-sensitivity C-reactive protein (hs-CRP) as marker of pneumonia. Panel a) Comparison of hs-CRP values in patients with (n = 239)
and patients without pneumonia (n = 216). Panel b) Comparison of serum hs-CRP values between patients with pneumonia and a diagnostic
chest X-ray (n = 125) and patients with pneumonia and a non-diagnostic chest X-ray (n = 114)
Fig. 2 Serum procalcitonin as marker of pneumonia. Panel a) Comparison of serum procalcitonin values in patients with (n = 239) and without
pneumonia (n = 216). Panel b) Comparison of serum procalcitonin values between patients with pneumonia and a diagnostic chest X-ray (n = 125)
and patients with pneumonia and a non-diagnostic chest X-ray (n = 114)
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76 F, mean age 79 ± 13). Neither hs-CRP (median CAP
vs HCAP 112.5, IQR 42.5–183.0, vs 127.0, IQR 46.5–
176.0, mg/L, age- and sex-adjusted p = 0.60) nor pro-
calcitonin values (median CAP vs HCAP 0.22, IQR
0.12–0.79, vs 0.31, IQR 0.12–1.93, ng/ml, age- and sex-
adjusted p = 0.56) were significantly different between
these two subgroups.
Moreover, in patients with pneumonia, CXR was diag-
nostic only in 125 subjects (52.3 %). Conversely, other
114 patients (47.6 %) had negative or inconclusive radio-
graphic findings and therefore diagnosis was established
by chest CT scan. As shown in Figs. 1 and 2, at an age-
and sex-adjusted analysis, both hs-CRP and procalcito-
nin were not significantly different between these two
subgroups. Pneumonia was complicated by sepsis, severe
sepsis or septic shock only in 11, 10 and 5 cases,
respectively (11 % overall).
Discussion
In a cohort of multimorbid elderly patients acutely
hospitalized with respiratory symptoms, serum hs-CRP
values >61 mg/L were significantly associated with a
diagnosis of pneumonia, irrespective of CAP/HCAP
categorization and results of CXR. On the other side,
serum procalcitonin levels were not significantly able
to discriminate between those patients with and those
patients without pneumonia.
Pneumonia in elderly patients may be a real diagnostic
challenge, as confirmed by the finding that in our case-
series CXR was negative or inconclusive in almost one
patient out of two. Many factors, including cognitive im-
pairment, lack of collaboration, low muscle strength and
disability, may contribute to this poor diagnostic per-
formance of CXR [27]. Thus, the diagnostic approach
should be multimodal, basing on a personalized ap-
proach and encompassing not only traditional imaging
techniques but also accurate laboratory tests. Unfortu-
nately, no known biomarker holds a sufficient sensitivity
and sensibility to be used alone as a valid diagnostic tool
for pneumonia, particularly in this setting, where comor-
bidities may act as strong confounders. This is also the
case of hs-CRP and procalcitonin. However, our results
strengthen the role of hs-CRP as a guide in the manage-
ment of acute respiratory symptoms in elderly patients.
In fact, the presence of serum hs-CRP values >61 mg/L
in a patient with acute respiratory symptoms strongly
suggests the diagnosis of pneumonia. Thus, diagnostic
Fig. 3 ROC curve of high-sensitivity C-reactive protein (hs-CRP) vs
pneumonia diagnosis. ROC curve showing the association of hs-CRP
levels at admission with the diagnosis of pneumonia in the studied
multimorbid elderly population (AUC 0.76, 95 % CI 0.72–0.79, age- and
sex-adjusted p < 0.0001, cut-off value 61 mg/L)
Table 2 Multivariate Cox regression models exploring the association between serum hs-CRP >61 mg/L and the diagnosis of
pneumonia in the study population (n = 455)
Parameter O.R. 95 % C.I. p
Model 1 (age- and sex-adjusted)
hs-CRP> 61 mg/L 3.88 2.58–5.81 <0.001
Age 0.98 0.97–1.01 0.17
Sex (F vs M) 0.59 0.39–0.89 0.01
Model 2 (fully-adjusted)
hs-CRP> 61 mg/L 3.59 2.35–5.48 <0.001
Age 0.98 0.96–1.01 0.09
Sex (F vs M) 0.52 0.34–0.,80 0.003
Setting of living (nursing home vs community) 1.99 1.18–3.36 0.009
Dementia 2.45 1.48–4.08 <0.001
Model 1 is age- and sex-adjusted. Model 2 is adjusted also for covariates that proved significantly different between patients with and without pneumonia at
univariate analysis (i.e. dementia and provenience from a nursing home). The cut-off value of hs-CRP was set at 61 mg/L according to the Youden index applied
to the ROC method
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techniques with a higher accuracy for pneumonia than
CXR, such as chest CT or, possibly, lung ultrasound,
might be performed [28]. On the other side, when hs-CRP
is ≤61 mg/L, other diagnostic hypotheses, including
COPD exacerbation, asthma and acute heart failure, might
be pursued.
Our results instead do not support any diagnostic role
of procalcitonin, therefore suggesting that this laboratory
test should not be performed routinely in this particular
setting.
Up to date, very few studies have assessed the useful-
ness of these biomarkers for pneumonia diagnosis, fo-
cusing exclusively on hospitalized multimorbid elderly.
In a recent clinical study from Greece a good diagnostic
performance for both CRP and procalcitonin was dem-
onstrated in HCAP [7]. Another prospective study
showed that a significant, though late, rise in procalci-
tonin levels was associated with bacterial infections in
elderly inpatients, although this correlation could have
poor diagnostic usefulness [17].
In adult patients without significant comorbidities, the
measurement of serum procalcitonin is widely recom-
mended as an efficient biomarker of pneumonia, for
both diagnostic and prognostic purposes [5–16]. In
spite of this, nearly all studies that compared procalci-
tonin and CRP in pneumonia concluded that the latter
exhibits a diagnostic performance that is comparable
to, if not better than, that of procalcitonin [7, 9–11, 14, 20].
There is actually only one study clearly concluding that
procalcitonin is a better biomarker of pneumonia than
CRP [12], while another reported that both tests have no
advantages in clinical practice [19].
During the aging process, there may be several ele-
ments biasing the association between pneumonia and
elevation in serum of CRP or procalcitonin. For example,
multimorbid elderly subjects may face complex im-
munologic rearrangements with chronic exposure to a
variety of antigens promoting a subclinical inflammatory
status defined as inflammaging [29]. These phenomena
may result in a peculiar cytokine pattern, with impaired
procalcitonin release in response to antigens that gener-
ally promote its synthesis from extra-thyroidal sites in
adult subjects. Furthermore, the etiology of pneumonia
may also be associated with different cytokine activation
patterns [30]. Thus, immunologic changes that occur
with aging, variability in etiology of pneumonia, multi-
morbidity and polypharmacy may help explaining why
many participants to the present study did not exhibit
serum procalcitonin elevation despite a serious infection
was present. Moreover, only a small percentage of patients
with pneumonia (11 %) developed sepsis, severe sepsis or
septic shock. Since procalcitonin elevation is a known
marker of sepsis, this may help to explain the relatively
low levels of procalcitonin in the studied population.
Our results are consistent with those by van Vugt et
al., who found that a CRP >30 mg/L can improve diag-
nostic classification of patients with CAP in a large co-
hort of adults referred to primary care facilities [20].
Moreover, some authors have also demonstrated that
CRP dosage may be very useful in distinguishing CAP
from exacerbations of asthma or COPD, with optimal
sensitivity and specificity (respectively 0.91 and 0.93) at
a cut-off value of 48 mg/L [10].
These studies identified CRP cut-off values for pneu-
monia diagnosis lower than that found in our cohort
(i.e., 61 mg/L). This difference may be due to the high
multimorbidity burden of our patients. Chronic diseases
can represent triggers for CRP elevation and possible
confounding factors, accounting for the higher median
values of inflammatory parameters. Thus, further studies
are needed to confirm and validate the detected cut-off
value in populations with similar multimorbidity burden.
In our cohort, serum hs-CRP values were not statisti-
cally different when comparing patients with CAP and
HCAP. A prospective multicenter case–control study
carried out in Spain has recently demonstrated that mi-
crobial etiology of HCAP is similar to CAP, thus
highlighting that this classification may be important
only from an epidemiological, and not a clinical, point of
view [31]. The role of hs-CRP in pneumonia diagnosis
may thus be independent of this classification. However,
there are also studies that claim different etiology and
clinical course between CAP and HCAP [2]. The differ-
ent value of biomarkers in CAP and HCAP should
therefore be better investigated.
Some limitations should be taken into account when
interpreting the results of our study. First, the retro-
spective design did not allow to collect data about im-
portant covariates, such as functional and nutritional
status. Thus, further studies with a prospective design
are needed to confirm our findings. Second, the etiology
of pneumonia was available only in a minority of pa-
tients, and thus categorization of results according to
this aspect was not possible. Third, no data were avail-
able about the number of drugs taken by each patient,
particularly immunosuppressive drugs, even if the preva-
lence of comorbidities that chronically require these
medications was very small (below 5 %). However, some
evidence suggests that these drugs do not directly influ-
ence the concentration of either CRP or procalcitonin,
since the variation of serum levels is more strictly associ-
ated with the clinical course [32, 33]. Fourth, the elevated
clinical complexity of patients due to multimorbidity may
also carry out potential biases that cannot be completely
measured through CIRS. Finally, stratification of pneumo-
nia severity and prognosis with internationally-validated
indexes, like Pneumonia Severity Index (PSI) or CURB-65,
was not available for many patients, since it was generally
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performed in the Emergency Department and not re-
corded on documents included in our clinical records.
Conclusions
In a cohort of multimorbid patients aged more than 65
who required hospitalization for acute respiratory symp-
toms, serum procalcitonin lacks sufficient accuracy for
the diagnosis of pneumonia. Therefore, the routine pre-
scription of this laboratory test should be discouraged in
this setting. Conversely, hs-CRP elevation over 61 mg/L
implies a high risk of pneumonia, and might therefore
be useful for clinicians in guiding prescriptions of other
diagnostic tests, particularly when CXR findings are in-
conclusive. Prospective studies focused on this complex
population are needed to confirm these findings.
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